Clinical trials: Lipoprotein Disorder
Hyperlipidemia
Study of Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Inclisiran in Chinese Participants With Elevated Serum LDL-C
Study to evaluate the pharmacokinetics and pharmacodynamics of inclisiran treatment given as single subcutaneous injection in Chinese participants with elevated low-density lipoprotein cholesterol (LDL-C) despite treatment with…
- Trial name
- ORION-14 (NCT04774003)
- Testing
- 100 mg inclisiran sodium (equivalent to 94.5 mg inclisiran), 300 mg inclisiran sodium (equivalent to 284 mg inclisiran)
- Where
- 3 sites in China
- Volunteers
- 40 people
- Sponsor
- Novartis Pharmaceuticals
Cardiovascular Diseases, Dyslipidemias
Evaluation of Cascade Screening for Elevated Lipoprotein(a)
The aim of the current project is to evaluate the penetrance of elevated plasma Lp(a) levels in patients with atherosclerotic coronary artery disease to their first- and second-degree biological relatives based on data from a…
- Conditions
- Cardiovascular Diseases, Dyslipidemias, Hereditary Diseases
- Trial name
- LipoaScreen (NCT06157983)
- Testing
- measurement of lipoprotein(a)
- Where
- Sweden
- Volunteers
- 1,950 people
- Sponsor
- Karolinska Institutet
Atherosclerotic Cardiovascular Disease
Low-Density Lipoprotein Cholesterol Reduction With Alirocumab 150 mg Versus Inclisiran in Individuals Initiating Therapy in Routine Clinical Practice
The objective of this study is to evaluate LDL-C reduction over time among individuals initiating alirocumab 150 mg compared with inclisiran in routine clinical practice.
- Trial name
- NCT07615166
- Testing
- Alirocumab 150 mg, Inclisiran
- Where
- United States
- Volunteers
- 996 people
- Sponsor
- Sanofi
Pancreatic Carcinoma; Lipoprotein a; Overall Survival; Prognosis
Lipoprotein a is an Independent Risk Factor for Overall Survival in Patients With Pancreatic Cancer: a Propensity Score Matching Analysis
Background: This study aims to assess the prognostic significance of serum lipoprotein (a) [Lp (a)] levels on overall survival (OS) and progression free survival (PFS) in individuals diagnosed with pancreatic cancer through the…
- Trial name
- NCT06316466
- Testing
- Lp(a)
- Where
- China
- Volunteers
- 360 people
- Sponsor
- jingxue
Acute Coronary Syndrome, Myocardial Infarction
OptimiZation Of Lipid Lowering Therapies Using a Decision Support System In Patients With Acute Coronary Syndrome.
The goal of this clinical trial is to compare implementation of a Decision Support System (DSS) - aligned to the 2019 ESC/EAS Guidelines - in addition to routine clinical care versus routine clinical care without availability of…
- Trial name
- ZODIAC (NCT05844566)
- Testing
- Decision Support System (DSS)
- Where
- 42 sites in Italy, Spain and 1 more
- Volunteers
- 1,139 people
- Sponsor
- Imperial College London
Cardiovascular Diseases, Heart Diseases
Epidemiology of APO- and Lipoproteins in Elderly Women
To examine the complex interactions among the traditional cardiovascular risk factors, particularly lipoprotein and apoprotein levels, genetic and other characteristics, and lifestyle habits in elderly women.
- Conditions
- Cardiovascular Diseases, Heart Diseases, Coronary Disease
- Trial name
- NCT00005223
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Obesity, Dyslipidemia
Effect of Abdominal Obesity on Lipoprotein Metabolism
Abdominal obesity is strongly associated with dyslipidemia, which may account for the associated increased risk of atherosclerosis and coronary disease.
- Conditions
- Obesity, Dyslipidemia, Insulin Resistance
- Trial name
- NCT00438061
- Testing
- Weight loss by dietary restriction
- Where
- Australia
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- The University of Western Australia
Cerebrotendinous Xanthomatosis (CTX)
Evaluation of Carotid IMT and Atherogenic Risk Factors in Patients With Cerebrotendinous Xanthomatosis
The aim of the proposed study is to evaluate the risk for cardiovascular disease and 'atherogenic' features of the serum in CTX and to determine preclinical atherosclerosis.
- Trial name
- CTX (NCT01613898)
- Testing
- Blood tests
- Where
- Israel
- Volunteers
- 17 people
- Sponsor
- Sheba Medical Center
Hypercholesterolemia
(H.E.L.P.)Apheresis Therapy to Compare the Reduction of LDL (Low Density Lipoprotein) Cholesterol
The primary objective of the study is to demonstrate that the performance of the modified Plasmat® Futura H.E.L.P. Apheresis System is non-inferior to the current FDA approved Plasmat® Secura H.E.L.P Apheresis System for use…
- Trial name
- FUTURA (NCT00526058)
- Testing
- Secura then Futura, Futura then Secura
- Where
- 2 sites in United States
- Volunteers
- 18 people
- Sponsor
- B. Braun Medical Inc.
Elevated Lipoprotein(a), Cardiovascular Diseases
Drug-drug Interaction Study to Evaluate the Effect of ISIS 681257 on Warfarin
This is a single center, open label, single sequence, two-treatment, two-period drug-drug interaction study to evaluate the effect of multiple doses of ISIS 681257 on the pharmacokinetics of a single dose of warfarin.
- Trial name
- NCT03426033
- Testing
- ISIS 681257, Warfarin
- Where
- Canada
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Akcea Therapeutics
Nonalcoholic Steatohepatitis
Combination Obeticholic Acid (OCA) and Statins for Monitoring of Lipids (CONTROL)
This Phase 2, double-blind, randomized, placebo-controlled, multicenter study, with an open-label long-term safety extension (LTSE), will evaluate the effect of Obeticholic Acid, and the subsequent addition of statin therapy, on…
- Trial name
- CONTROL (NCT02633956)
- Testing
- Obeticholic Acid, Atorvastatin
- Where
- 22 sites in United States
- Volunteers
- 84 people
- Sponsor
- Intercept Pharmaceuticals
Dyslipidemias
Effect of Virgin Coconut Oil (VCO) on Cardiometabolic Parameters in Patients With Dyslipidemia
The present research will help to assess the effect of virgin coconut oil on cholesterol level and also will help to know whether virgin coconut oil can reduce the risk of heart diseases or not.
- Trial name
- NCT03906539
- Testing
- Atorvastatin 10mg, Virgin Coconut Oil (VCO)
- Where
- India
- Volunteers
- 150 people
- Sponsor
- All India Institute of Medical Sciences, Bhubaneswar
Hypertriglyceridemia
Effects of Lovaza on Lipoprotein Composition and Function in Mild Hypertriglyceridemia
This study will build upon a previous finding that showed a triglyceride lowering effect of prescription omega-3 in combined therapy with statins.
- Trial name
- ELLF (NCT00959842)
- Testing
- Lovaza
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Sanford Research
Lipoprotein Disorder
A Study of LY3819469 in Participants With Elevated Lipoprotein(a) [Lp(a)]
The main purpose of this study is to determine the efficacy and safety of LY3819469 in adults with elevated lipoprotein(a). The study will lasts about 20 months.
- Trial name
- NCT05565742
- Testing
- LY3819469
- Where
- 80 sites in United States, Argentina and 8 more
- Volunteers
- 320 people
- Sponsor
- Eli Lilly and Company
Dyslipidemia
A Study to Assess the Efficacy, Safety and Tolerability of Different Doses of AZD0780 in Patients With Dyslipidemia
The primary purpose of this study is to measure the effect of different daily doses of AZD0780 on Low-Density Lipoprotein (LDL-C) levels compared with placebo in participants with dyslipidemia.
- Trial name
- PURSUIT (NCT06173570)
- Testing
- AZD0780
- Where
- 55 sites in United States, Canada and 6 more
- Volunteers
- 428 people
- Sponsor
- AstraZeneca
Acute Chest Syndrome
ST Elevation in Acute Chest Pain; Could Measurement of Lipoprotein-associated Phospholipase A2 (Lp-PLA2) be Helpful to the Clinician?
A blood test (2-3 cc peripheral venous blood) drawn /used from already available required lab tests to distinguish between pericarditis accompanied with electrocardiogram (ECG) signs mimicking infarction.
- Trial name
- NCT01041339
- Where
- Israel
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Alexhander Izhaki
Hypercholesterolemia, Coronary Disease
Co-administration Study in Patients With Elevated Cholesterol and Coronary Heart Disease (0653-802)(COMPLETED)
The purpose of this study is to investigate additional cholesterol lowering effects in patients with coronary heart disease by giving an investigational drug with a patient's current approved cholesterol lowering medication.
- Trial name
- NCT00092612
- Testing
- MK0653, ezetimibe
- Volunteers
- 372 people
- Sponsor
- Organon and Co
Hyperlipoproteinemia (a)
An Open Label Extension (OLE) Study to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)
This non-randomized, open-label extension study provides post-trial access to pelacarsen (TQJ230) to participants in Germany with hyperlipoproteinemia(a) and established cardiovascular disease who have successfully completed the…
- Trial name
- OLE (NCT05900141)
- Testing
- Pelacarsen
- Where
- 9 sites in Germany
- Volunteers
- 41 people
- Sponsor
- Novartis Pharmaceuticals
Hyperlipidemia
Comparison of LDL Particle Count With Other Available Lipid Tests
Despite the wide availability of advanced lipoprotein tests, no reference standard exists for Low Density Lipoprotein Cholesterol (LDL-C) due to inherent problems with each of the assays.
- Trial name
- LIPID (NCT02298894)
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Scripps Clinic
Serum, Lipoprotein(A)
Serum Lipoprotein-a as a Marker of Severity of Coronary Artery Disease in Aortic Valve Sclerosis Patients
This work aimed to evaluate the association of serum level of Lp(a) with the severity of coronary artery disease (CAD) in aortic valve sclerosis (AVS) patients.
- Conditions
- Serum, Lipoprotein(A), Severity, Coronary Artery Disease
- Trial name
- NCT07209631
- Testing
- Serum Lipoprotein-a level
- Where
- Egypt
- Volunteers
- 100 people
- Sponsor
- Sohag University